Literature DB >> 9648590

Retinoblastoma protein expression in ovarian epithelial neoplasms.

T H Niemann1, T L Trgovac, V R McGaughy, G S Lewandowski, L J Copeland.   

Abstract

Progress has been made in identifying the molecular changes that occur in ovarian carcinoma; still our understanding of these changes and their interactions remains incomplete. In the present study the authors examined the expression of retinoblastoma protein, a tumor suppressor protein, in a spectrum of ovarian epithelial tumors including cystadenomas, low-malignant-potential tumors, and carcinomas. A heterogeneous pattern of reactivity was observed in all of the cystadenomas, in all of the low-malignant-potential tumors, and in a majority (27/34) of the carcinomas. The remaining carcinomas showed either a complete absence of reactivity or a pattern of altered reactivity characterized by areas of tumor with intact reactivity adjacent to zones of tumor with a complete absence of reactivity. There was no significant association between grade or stage and absent/altered reactivity. We conclude that alterations of retinoblastoma protein expression are uncommon in ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648590     DOI: 10.1006/gyno.1998.5015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

Review 1.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.

Authors:  S Kommoss; A du Bois; R Ridder; M J Trunk; D Schmidt; J Pfisterer; F Kommoss
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.